Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed non-small cell lung cancer
• * Stage IB (T2, N0), II (T1 or T2, N1 or T3, N0), or IIIA (T3, N1)
• * Potentially resectable disease
• No large central primary tumors in proximity to significant blood vessels
• No bronchoscopically evident endobronchial tumors
• At least 1 unidimensionally measurable lesion
• * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-1 OR
• Karnofsky 70-100%
• Life expectancy:
• More than 12 months
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• No history of an inherited bleeding disorder
• No inherited predisposition to a hypercoagulable state
• No clinically evident hypercoagulable state or bleeding diathesis
• Hepatic:
• Bilirubin less than 1.5 times upper limit of normal (ULN)
• AST/ALT no greater than 2.5 times ULN
• INR less than 1.5
• PTT less than 36 seconds
• Renal:
• Creatinine less than 1.5 times ULN OR
• Creatinine clearance at least 60 mL/min
• No nephrotic syndrome
• Urine protein no greater than 0.5 g/24 hours
• Cardiovascular:
• No poorly controlled hypertension (greater than 150 mm Hg systolic and/or greater than 100 mm Hg diastolic) despite treatment
• No uncompensated coronary artery disease
• No myocardial infarction within the past 6 months
• No clinically significant or severe peripheral vascular disease
• No inherited predisposition to thrombosis
• No deep venous or arterial thrombosis
• No symptomatic congestive heart failure
• No unstable angina pectoris within the past 6 months
• No cardiac arrhythmia
• No transient ischemic attack within the past 6 months
• No cerebrovascular accident within the past 6 months
• No other arterial thromboembolic event within the past 6 months
• Pulmonary:
• No hemoptysis
• No pulmonary embolism
• Other:
• No history of allergic reactions to compounds of similar chemical or biologic composition to study drugs
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No psychiatric illness or social situation that would preclude study compliance
• No significant traumatic injury within the past 28 days
• No uncontrolled concurrent illness
• No ongoing or active infection
• No serious, non-healing wound, ulcer, or bone fracture
• No other active malignancy
• No requirement for full-dose anticoagulation or thrombolytic therapy
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior biologic therapy for this cancer
• No concurrent prophylactic growth factors (e.g., epoetin alfa, filgrastim \[G-CSF\], or sargramostim \[GM-CSF\])
• Chemotherapy:
• No prior chemotherapy for this cancer
• Prior chemotherapy for another malignancy allowed provided the prior malignancy was curatively treated and is currently controlled
• Endocrine therapy:
• No prior endocrine therapy for this cancer
• Radiotherapy:
• No prior radiotherapy for this cancer
• Prior radiotherapy for another malignancy allowed provided the prior malignancy was curatively treated and is currently controlled
• No concurrent radiotherapy
• Surgery:
• Prior diagnostic bronchoscopy, mediastinoscopy, or CT-guided biopsy allowed
• At least 28 days since prior major surgical procedure or open biopsy
• Other:
• No other concurrent investigational agents
• No other concurrent anticancer investigational or commercial agents or therapies
• No concurrent combination antiretroviral therapy for HIV-positive patients
• Concurrent low-dose warfarin for maintenence of preexisting, permanent, indwelling IV catheters allowed provided INR less than 1.5